Research
Hormonal
PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).
Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.
StrongSupportsmedium confidence
Compared with PAP, PAP+semaglutide was associated with lower incident PH at 1 year (RR:0.45; 95% CI:0.44–0.56, NNT=38) and at 3 years (RR:0.50; 95% CI:0.45–0.54, NNT=23), and lower mortality at 1 year (RR:0.35; 95% CI:0.33–0.37, NNT=12) and 3 years (RR:0.37; 95% CI:0.35–0.39, NNT=8);
Why this rating
Based on the large cohort size and retrospective study design.
Source
Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP
Samuel Governor et al. · medRxiv · 2026
cohort · n=288587Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →